EMA Authorised: Hetronifly (serplulimab) — Accord Healthcare S.L.U.

View source ↗

Summary

European Medicines Agency authorises Hetronifly (serplulimab) for multiple indications including small cell lung cancer, non-small cell lung carcinoma, and esop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Non-small-cell Lung
• Esophageal Squamous Cell Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• Hetronifly (serplulimab)

Snippet

Status: Authorised. Therapeutic area: Small Cell Lung Carcinoma;Carcinoma, Non-Small-Cell Lung;Esophageal Squamous Cell Carcinoma. MAH: Accord Healthcare S.L.U.. Decision date: 19/06/2026